Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Articles published by Amylyx Pharmaceuticals, Inc.
< Previous
1
2
3
Next >
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
June 13, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
June 03, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Presentation of New Analysis of CENTAUR Trial Results at the European Network to Cure ALS 2022 Meeting
May 26, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy/Ventilation-free Survival and Reduced Occurrence of First Hospitalization
May 16, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results
May 12, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS
May 05, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Oral Presentation of Safety and Tolerability Data on AMX0035 from Clinical Trials at 2022 American Academy of Neurology Annual Meeting
April 02, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Reports Full Year 2021 Financial Results
March 30, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting on AMX0035 for the Treatment of ALS
March 30, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Stock Trading Halted Today
March 30, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on AMX0035
March 28, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Launch of U.S. Expanded Access Program for AMX0035
March 18, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces EMA Validation of Marketing Authorisation Application (MAA) for AMX0035 for the Treatment of ALS
February 25, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Expands Executive Team with Appointment of Gina M. Mazzariello as Chief Legal Officer and General Counsel
February 23, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces FDA Advisory Committee Meeting to Review New Drug Application for AMX0035 for the Treatment of ALS Scheduled for March 30, 2022
February 16, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Pricing of Upsized Initial Public Offering of Common Stock
January 06, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Submits Marketing Authorization Application (MAA) for AMX0035 for the Treatment of ALS
January 04, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Announces Launch of Initial Public Offering
January 03, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application (NDA) for AMX0035 for the Treatment of ALS
December 29, 2021
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Announces Results from PEGASUS Trial of AMX0035 in Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 09, 2021
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Announces Participants Dosed in the Global Phase 3 PHOENIX Study of AMX0035 in ALS
November 04, 2021
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Submits New Drug Application (NDA) for AMX0035 for the Treatment of ALS
November 02, 2021
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Hires Stéphanie Hoffmann-Gendebien, MBA, as Head, General Manager EMEA
October 26, 2021
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Announces Plan to Submit New Drug Application (NDA) for AMX0035 for the Treatment of ALS in the Coming Months
September 15, 2021
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Donates CENTAUR Clinical Trial Data and Participant Samples to Help Advance Science in ALS for Future Treatments and Discoveries
September 13, 2021
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Announces Health Canada Accepts for Review the New Drug Submission for AMX0035 for the Treatment of ALS
August 31, 2021
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Closes $135M Series C Financing Led by Viking Global Investors to Support Late Stage Development of Lead Product Candidate AMX0035 for the Treatment of ALS
July 20, 2021
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Strengthens Board of Directors with Appointment of Daphne Quimi, Chief Financial Officer of Amicus Therapeutics
June 29, 2021
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Files New Drug Submission for AMX0035 for the Treatment of ALS in Canada
June 14, 2021
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.